|
|
 |
|
Viewing report
|
|
|
|
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
Spectra Intelligence , April 2006, Pages: 369
This comprehensive report is designed to present a state-of-the-art view of chemotherapy approaches to the treatment of cancer and an assessment of the critical parameters of drug discovery and development that may lead to the introduction of new oncology drugs with great therapeutic and market potential over the next decade. The oncology market is currently the fastest growing in the pharmaceutical industry, driven by the explosion of potential therapeutic targets revealed by the molecular genetic assessments of cancer biology and fuelled by the magnitude of the disease worldwide, which shows every indication of increased incidence and sustained mortality rates over the next decade. Currently, there are 25 million people afflicted with cancer worldwide, and the World Health Organization (WHO) predicts that cancer rates may increase by 50% from 10 million cases in 2000 to 15 million cases in 2015. Moreover, the Association for International Cancer Research (AICR) estimates that by 2020, there will be 10 million deaths from cancer. Even in developed nations, approximately 50% of patients diagnosed with cancer will eventually die of this disease. The challenges are great, but the world of molecular medicine and biopharmaceuticals has presented great opportunities to discover and develop new pharmacological approaches with prospects for greater therapeutic efficacy and more promising clinical outcome.
In this report, Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities, the reader will be presented with an expert perspective on oncology therapeutics, drug development, and commercial opportunities within the field. The introductory chapter is designed to provide a global perspective on the many facets of cancer that will affect the discovery, development and marketing of oncology pharmaceuticals over the next decade. Among the critical disease parameters are the global epidemiology of cancer, which includes current incidence, survival and mortality trends for the most common cancers worldwide. This assessment is designed to focus attention on the types of cancer that may be most appropriately targeted for treatment research and development based on these current global statistics.
These statistics also highlight the types of cancer that continue to be most refractory to current treatment approaches, suggesting areas for future research in drug discovery. Each of the many common cancers is assessed in this chapter with respect to its aetiology, pathophysiology, diagnosis, current treatment options, and clinical outcomes.
Chapter 2 specifically focuses on the nature of the cancer problem with respect to the challenges and obstacles that need to be addressed to develop more clinically effective approaches to the treatment of cancer. These defining therapeutic parameters have their origins in tumour biology whose presentation includes recent developments in molecular biology that have facilitated a better understanding of drug/radiation treatment responses in haematological and solid tumour malignancies. This discussion also describes the important disease parameters that contribute to the clinical problems of therapy resistance, disease recurrence and progression that present significant obstacles to successful treatment approaches.
The pharmacology and drug delivery applications for clinical therapeutics that have been used successfully to treat specific types of cancer are highlighted as models for successful therapeutic approaches. Additionally, the pharmacological principles involved in the treatment of cancer are covered for each of the important classes of cancer therapeutics. Another important focus of this chapter is novel preclinical treatment approaches based on the most recent discoveries in tumour biology and our current understanding of the biological and pharmacological obstacles to successful treatment. This includes a description of the newest technologies used in cancer drug research and development as well as prospects for advances in technological developments.
In Chapter 3 all chemotherapeutic agents currently used to treat cancer are presented and organized into major therapeutic groups based on common mechanisms of action. This chapter also discusses clinical assessments and standard chemotherapy regimens employed in the treatment of cancer. Additionally, possible market opportunities for chemotherapy drugs are presented to include reformulation potential through novel drug delivery systems.
Chapter 4 contains a summary of the market for chemotherapies including an overview of trends, estimates of current and future market values, and outlook for the global oncology sector. The chapter also provides important coverage of issues associated with healthcare costs and reimbursement, such as insurance coverage and national healthcare plans as they relate to the marketing of oncology products. All of the major healthcare issues that affect pharmacoeconomic parameters associated with the successful marketing of oncology products are also detailed in this chapter. Furthermore, Chapter 4 includes forecasts of market potential based on increasing/decreasing cancer prevalence and the prediction of global sales from 2005 to 2016 for each of the major chemotherapeutics used in the treatment of specific types of cancer. Further discussion of market factors relevant to newly introduced oncology products including efficacy, potential market outlook with projected sales based on key pharmacoenconomic and clinical data, is also presented.
Chapter 5 directly assesses the potential of clinical phase chemotherapeutics to generate new opportunities to treat cancer successfully. Numerous oncology products in clinical development are reviewed based on clinical assessment and outcome. Selected oncology products are discussed in detail with respect to therapeutic category, mechanism of action, clinical study data, market potential, main competitors and commercial data. This chapter also discusses general trends in global cancer markets to impact cancer drugs in research and development. Topics covered include therapeutic classes, targets, and novel biopharmaceuticals that are currently in clinical development.
Many of the new areas of research that may hold great future clinical promise are discussed in Chapter 6. The first section outlines the current areas of research and development that may lead to the development of important new treatment approaches over the next few years. New developments in each of these areas are further presented with respect to their potential for the development of promising clinical approaches in treating cancer.
Chapter 6 also covers all of the major therapeutic and preventive cancer research themes that are the basis for drug development. Among the general therapeutic clinical research areas discussed are emerging biotechnologies, immunotherapies including recombinant vaccines, nanoparticle technology, and small molecule targeted therapeutics. Products in each of these categories are discussed in detail with respect to their ongoing clinical assessment and market forecast for investigative/experimental oncology products. The final chapter provides an assessment of some of the major pharmaceutical and biotechnology companies currently engaged in oncology product development. Leading cancer research-based companies are discussed in relation to marketed oncology products that are driving the revenue growth and those specialized in oncology discovery and clinical drug development.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Cancer Chemotherapy: Basic Science to the Clinic
Cancer Therapeutics Markets
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
The Cancer Clock
Drug Delivery in Cancer - Technologies, Markets and Companies
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Prostate Cancer Therapeutics - Global Strategic Business Report
European Bladder Cancer Therapeutics Markets
Cancer Therapies - Global Strategic Business Report
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
|
|
|
|
